reported the results from a Phase I clinical trial (NCT03060356) evaluating the safety and feasibility of intravenously delivered mRNA electroporation-generated second generation c-Met-redirected CAR-Ts in patients with metastatic or unresectable melanoma or TNBC with more than 30% c-Met expression (190). The gene discussed is MET; the disease is melanoma.